Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Baxter International Inc. stock logo
BAX
Baxter International
$16.75
+0.8%
$17.82
$15.73
$32.68
$8.58B0.627.85 million shs7.64 million shs
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$55.98
-1.5%
$66.69
$55.88
$109.50
$84.49B0.6218.10 million shs12.54 million shs
DexCom, Inc. stock logo
DXCM
DexCom
$59.48
-0.9%
$65.60
$54.11
$89.98
$23.17B1.44.80 million shs5.53 million shs
Fresenius SE & Co. stock logo
FSNUY
Fresenius SE & Co.
$11.61
-3.1%
$13.19
$11.52
$33.93
$26.99B0.68139,720 shs170,993 shs
ResMed Inc. stock logo
RMD
ResMed
$207.92
-0.7%
$232.33
$198.64
$293.81
$30.51B0.841.28 million shs1.85 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Baxter International Inc. stock logo
BAX
Baxter International
-2.95%-6.71%+0.44%-20.48%-45.03%
Boston Scientific Corporation stock logo
BSX
Boston Scientific
-1.17%-4.24%-10.76%-25.85%-46.29%
DexCom, Inc. stock logo
DXCM
DexCom
-3.05%+0.29%-4.40%-16.02%-25.90%
Fresenius SE & Co. stock logo
FSNUY
Fresenius SE & Co.
-5.07%-3.09%-7.64%-20.42%-4.05%
ResMed Inc. stock logo
RMD
ResMed
+1.34%-4.28%-7.27%-20.90%-13.60%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Baxter International Inc. stock logo
BAX
Baxter International
$16.75
+0.8%
$17.82
$15.73
$32.68
$8.58B0.627.85 million shs7.64 million shs
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$55.98
-1.5%
$66.69
$55.88
$109.50
$84.49B0.6218.10 million shs12.54 million shs
DexCom, Inc. stock logo
DXCM
DexCom
$59.48
-0.9%
$65.60
$54.11
$89.98
$23.17B1.44.80 million shs5.53 million shs
Fresenius SE & Co. stock logo
FSNUY
Fresenius SE & Co.
$11.61
-3.1%
$13.19
$11.52
$33.93
$26.99B0.68139,720 shs170,993 shs
ResMed Inc. stock logo
RMD
ResMed
$207.92
-0.7%
$232.33
$198.64
$293.81
$30.51B0.841.28 million shs1.85 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Baxter International Inc. stock logo
BAX
Baxter International
-2.95%-6.71%+0.44%-20.48%-45.03%
Boston Scientific Corporation stock logo
BSX
Boston Scientific
-1.17%-4.24%-10.76%-25.85%-46.29%
DexCom, Inc. stock logo
DXCM
DexCom
-3.05%+0.29%-4.40%-16.02%-25.90%
Fresenius SE & Co. stock logo
FSNUY
Fresenius SE & Co.
-5.07%-3.09%-7.64%-20.42%-4.05%
ResMed Inc. stock logo
RMD
ResMed
+1.34%-4.28%-7.27%-20.90%-13.60%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Baxter International Inc. stock logo
BAX
Baxter International
1.92
Reduce$19.9118.89% Upside
Boston Scientific Corporation stock logo
BSX
Boston Scientific
2.92
Moderate Buy$93.9167.76% Upside
DexCom, Inc. stock logo
DXCM
DexCom
2.88
Moderate Buy$83.5040.38% Upside
Fresenius SE & Co. stock logo
FSNUY
Fresenius SE & Co.
3.00
BuyN/AN/A
ResMed Inc. stock logo
RMD
ResMed
2.73
Moderate Buy$286.1837.64% Upside

Current Analyst Ratings Breakdown

Latest BAX, BSX, FSNUY, DXCM, and RMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/4/2026
DexCom, Inc. stock logo
DXCM
DexCom
Reiterated RatingBuy$84.00 ➝ $79.00
5/1/2026
DexCom, Inc. stock logo
DXCM
DexCom
Set Price Target$77.00
5/1/2026
ResMed Inc. stock logo
RMD
ResMed
Set Price Target$225.00
5/1/2026
DexCom, Inc. stock logo
DXCM
DexCom
Set Price Target$80.00
5/1/2026
DexCom, Inc. stock logo
DXCM
DexCom
Set Price Target$75.00
5/1/2026
DexCom, Inc. stock logo
DXCM
DexCom
Set Price Target$81.00
5/1/2026
DexCom, Inc. stock logo
DXCM
DexCom
Set Price TargetBuy$95.00 ➝ $100.00
5/1/2026
DexCom, Inc. stock logo
DXCM
DexCom
Set Price TargetUnderweight$72.00 ➝ $67.00
5/1/2026
Baxter International Inc. stock logo
BAX
Baxter International
Lower Price Target$22.00 ➝ $20.00
5/1/2026
Baxter International Inc. stock logo
BAX
Baxter International
Lower Price Target$20.00 ➝ $19.00
5/1/2026
Baxter International Inc. stock logo
BAX
Baxter International
Boost Price Target$17.00 ➝ $19.00
(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Baxter International Inc. stock logo
BAX
Baxter International
$11.24B0.77$5.73 per share2.92$11.65 per share1.44
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$20.07B4.14$3.97 per share14.09$17.57 per share3.19
DexCom, Inc. stock logo
DXCM
DexCom
$4.66B4.92$2.74 per share21.68$7.66 per share7.77
Fresenius SE & Co. stock logo
FSNUY
Fresenius SE & Co.
$25.87B1.01$1.52 per share7.66$9.93 per share1.17
ResMed Inc. stock logo
RMD
ResMed
$5.15B5.89$11.12 per share18.69$44.56 per share4.67
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Baxter International Inc. stock logo
BAX
Baxter International
-$957M-$2.13N/A8.422.68-9.70%16.15%5.24%N/A
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$2.90B$2.3923.4214.931.0417.29%19.17%10.77%7/22/2026 (Estimated)
DexCom, Inc. stock logo
DXCM
DexCom
$836.30M$2.3425.4219.761.0419.31%33.33%13.19%N/A
Fresenius SE & Co. stock logo
FSNUY
Fresenius SE & Co.
$1.43B$0.6318.4310.18N/A5.71%10.31%4.78%5/6/2026 (Estimated)
ResMed Inc. stock logo
RMD
ResMed
$1.40B$10.3720.0517.171.3327.44%25.35%18.69%N/A

Latest BAX, BSX, FSNUY, DXCM, and RMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2026N/A
Fresenius SE & Co. stock logo
FSNUY
Fresenius SE & Co.
$0.2535N/AN/AN/A$6.79 billionN/A
4/30/2026Q1 2026
Baxter International Inc. stock logo
BAX
Baxter International
$0.31$0.36+$0.05-$0.03$2.62 billion$2.70 billion
4/30/2026Q1 2026
DexCom, Inc. stock logo
DXCM
DexCom
$0.47$0.56+$0.09$0.51$1.17 billion$1.19 billion
4/30/2026Q3 2026
ResMed Inc. stock logo
RMD
ResMed
$2.79$2.86+$0.07$2.74$1.42 billion$1.43 billion
4/22/2026Q1 2026
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$0.7930$0.80+$0.0070$0.90$5.19 billion$5.20 billion
2/25/2026Q4 2025
Fresenius SE & Co. stock logo
FSNUY
Fresenius SE & Co.
N/A$0.28N/A$0.18N/A$6.94 billion
2/12/2026Q4 2025
Baxter International Inc. stock logo
BAX
Baxter International
$0.53$0.44-$0.09-$2.19$2.82 billion$2.97 billion
2/12/2026Q4 2025
DexCom, Inc. stock logo
DXCM
DexCom
$0.65$0.68+$0.03$0.68$1.25 billion$1.26 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Baxter International Inc. stock logo
BAX
Baxter International
$0.040.24%-11.54%N/A N/A
Boston Scientific Corporation stock logo
BSX
Boston Scientific
N/AN/AN/AN/AN/A
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
Fresenius SE & Co. stock logo
FSNUY
Fresenius SE & Co.
$0.191.64%N/A30.16%N/A
ResMed Inc. stock logo
RMD
ResMed
$2.401.15%+6.33%23.14%13 Years

Latest BAX, BSX, FSNUY, DXCM, and RMD Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2026
Baxter International Inc. stock logo
BAX
Baxter International
quarterly$0.010.23%5/29/20265/29/20267/1/2026
4/30/2026
ResMed Inc. stock logo
RMD
ResMed
quarterly$0.601.12%5/14/20265/14/20266/18/2026
2/11/2026
Baxter International Inc. stock logo
BAX
Baxter International
quarterly$0.010.2%2/27/20262/27/20264/1/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Baxter International Inc. stock logo
BAX
Baxter International
1.43
1.85
1.23
Boston Scientific Corporation stock logo
BSX
Boston Scientific
0.42
1.90
1.08
DexCom, Inc. stock logo
DXCM
DexCom
0.42
1.95
1.64
Fresenius SE & Co. stock logo
FSNUY
Fresenius SE & Co.
0.47
1.32
1.00
ResMed Inc. stock logo
RMD
ResMed
0.06
3.01
2.33

Institutional Ownership

CompanyInstitutional Ownership
Baxter International Inc. stock logo
BAX
Baxter International
90.19%
Boston Scientific Corporation stock logo
BSX
Boston Scientific
89.07%
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
Fresenius SE & Co. stock logo
FSNUY
Fresenius SE & Co.
N/A
ResMed Inc. stock logo
RMD
ResMed
54.98%

Insider Ownership

CompanyInsider Ownership
Baxter International Inc. stock logo
BAX
Baxter International
0.17%
Boston Scientific Corporation stock logo
BSX
Boston Scientific
0.34%
DexCom, Inc. stock logo
DXCM
DexCom
0.28%
Fresenius SE & Co. stock logo
FSNUY
Fresenius SE & Co.
N/A
ResMed Inc. stock logo
RMD
ResMed
0.65%
CompanyEmployeesShares OutstandingFree FloatOptionable
Baxter International Inc. stock logo
BAX
Baxter International
37,500516.47 million515.38 millionOptionable
Boston Scientific Corporation stock logo
BSX
Boston Scientific
59,0001.49 billion1.48 billionOptionable
DexCom, Inc. stock logo
DXCM
DexCom
11,000385.87 million384.79 millionOptionable
Fresenius SE & Co. stock logo
FSNUY
Fresenius SE & Co.
178,3942.25 billionN/ANot Optionable
ResMed Inc. stock logo
RMD
ResMed
10,600145.68 million144.73 millionOptionable

Recent News About These Companies

Here's Why ResMed (RMD) is a Strong Growth Stock
Mizuho Securities Keeps Their Buy Rating on Resmed (RMD)
ResMed Inc. 2026 Q3 - Results - Earnings Call Presentation
ResMed Earnings Call Highlights Margin Strength, Growth
ResMed Inc. $RMD Stake Cut by Danske Bank A S
ResMed Q3 Earnings Call Highlights

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Baxter International stock logo

Baxter International NYSE:BAX

$16.75 +0.13 (+0.76%)
Closing price 05/5/2026 03:59 PM Eastern
Extended Trading
$16.77 +0.02 (+0.14%)
As of 05/5/2026 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Boston Scientific stock logo

Boston Scientific NYSE:BSX

$55.98 -0.87 (-1.53%)
Closing price 05/5/2026 03:59 PM Eastern
Extended Trading
$56.49 +0.51 (+0.91%)
As of 05/5/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

DexCom stock logo

DexCom NASDAQ:DXCM

$59.48 -0.56 (-0.93%)
Closing price 05/5/2026 04:00 PM Eastern
Extended Trading
$59.48 0.00 (0.00%)
As of 05/5/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Fresenius SE & Co. stock logo

Fresenius SE & Co. OTCMKTS:FSNUY

$11.61 -0.37 (-3.09%)
As of 05/5/2026 03:58 PM Eastern

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

ResMed stock logo

ResMed NYSE:RMD

$207.92 -1.51 (-0.72%)
Closing price 05/5/2026 03:59 PM Eastern
Extended Trading
$206.60 -1.32 (-0.64%)
As of 05/5/2026 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.